Zealand Pharma A/S (CPH:ZEAL)

Market Cap	25.54B
Revenue (ttm)	55.69M
Net Income (ttm)	-1.19B
Shares Out	70.99M
EPS (ttm)	-17.26
PE Ratio	n/a
Forward PE	3.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	635,486
Average Volume	805,116
Open	354.70
Previous Close	353.40
Day's Range	353.60 - 366.80
52-Week Range	351.40 - 972.00
Beta	0.56
RSI	32.64
Earnings Date	Aug 14, 2025

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 335
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: ZEAL

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.